A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
NCT ID: NCT02569710
Last Updated: 2019-07-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
161 participants
INTERVENTIONAL
2015-10-31
2018-05-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection
NCT02765490
A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive
NCT02993250
A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers
NCT02512562
A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection
NCT03099135
First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
NCT02339207
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohorts 1 and 2 (Without Cirrhosis) : AL-335+ODV+SMV
Treatment-naïve non-cirrhotic Hepatitis C virus (HCV)-infected participants will receive AL-335 and Odalasvir (ODV) with Simeprevir (SMV) for 8 weeks.
AL-335
AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
Odalasvir (ODV)
ODV capsules will be administered in a dose range of 25 to 50 mg.
Simeprevir (SMV)
SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
Cohort 1b (Without Cirrhosis) : AL-335+ODV
Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV for 8 weeks.
AL-335
AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
Odalasvir (ODV)
ODV capsules will be administered in a dose range of 25 to 50 mg.
Cohort 3 (Without Cirrhosis) : AL-335+ODV+SMV
Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV for 6 weeks.
AL-335
AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
Odalasvir (ODV)
ODV capsules will be administered in a dose range of 25 to 50 mg.
Simeprevir (SMV)
SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
Cohort 4 (Without Cirrhosis) : AL-335+ODV
Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV up to 8 or 12 weeks.
AL-335
AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
Odalasvir (ODV)
ODV capsules will be administered in a dose range of 25 to 50 mg.
Cohort 5 (Without Cirrhosis) : AL-335+ODV + SMV
Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV up to 8 or 12 weeks.
AL-335
AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
Odalasvir (ODV)
ODV capsules will be administered in a dose range of 25 to 50 mg.
Simeprevir (SMV)
SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
Cohorts 6, 7, 8 and 12 (With Cirrhosis) : AL-335+ODV+SMV
Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 8 weeks.
AL-335
AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
Odalasvir (ODV)
ODV capsules will be administered in a dose range of 25 to 50 mg.
Simeprevir (SMV)
SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
Cohorts 9, 10 and 11 (With Cirrhosis) : AL-335+ODV+SMV
Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 12 weeks.
AL-335
AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
Odalasvir (ODV)
ODV capsules will be administered in a dose range of 25 to 50 mg.
Simeprevir (SMV)
SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
Cohorts 12 to 15: AL-335+ODV With/without SMV
Based on safety, pharmacokinetic (PK), and viral load data, the treatment duration (4 to 12 weeks) and dose levels (AL-335: 400-1,200 milligram \[mg\], ODV: 25-50 mg with/without SMV: 75-150 mg) may be changed for ongoing and future cohorts (up to 15) after obtaining agreement from the Sponsor and the Principal Investigator.
AL-335
AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
Odalasvir (ODV)
ODV capsules will be administered in a dose range of 25 to 50 mg.
Simeprevir (SMV)
SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AL-335
AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
Odalasvir (ODV)
ODV capsules will be administered in a dose range of 25 to 50 mg.
Simeprevir (SMV)
SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. In the Investigator's opinion, the participant is able to understand and comply with protocol requirements, instructions, and protocol stated restrictions and is likely to complete the study as planned
3. Male or female, 18-70 years of age
4. Body mass index (BMI) 18-35 kilogram per meter square (kg/m\^2), inclusive
5. A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin) pregnancy test at screening
6. Female participants must either:
* not be of childbearing potential defined as: i. Postmenopausal for at least 12 months (that is \[i.e.\], 2 years of amenorrhea without an alternative medical cause) and a serum follicle stimulating hormone (FSH) level in the postmenopausal range (per reference laboratory), OR ii. Surgically sterile (example \[e.g.\], underwent total hysterectomy, bilateral oophorectomy, or bilateral tubal ligation/bilateral tubal clips without reversal operation), or otherwise incapable of becoming pregnant, OR
* be of childbearing potential AND
* not heterosexually active (e.g., abstinent or homosexual) from screening until 6 months after study drug administration (or longer, if dictated by local regulations), OR
* if heterosexually active
* have a vasectomized partner (confirmed sterile per verbal account of the participant), OR
* using an acceptable method of birth control from screening and agree to continue to use the same method of contraception throughout the study and for 6 months after study drug administration (or longer, if dictated by local regulations). Oral hormone based contraceptives are not allowed from 14 days before the planned study drug administration until 6 months after the last dose of treatment due to the potential for drug-drug interactions which might undermine their efficacy. An intrauterine device (IUD), being either hormonal (i.e., Intra-Uterine System \[IUS\*\]) or non-hormonal, is considered highly effective and reliable; therefore participants using an IUD/IUS are not required to use additional contraceptive methods (no double-barrier method is required). Other non-oral hormone-based contraception methods (e.g., injectable, implants, transdermal system, vaginal ring) may be continued, but as the interaction of the study drug with hormone-based contraception is unknown, these methods are not considered to be reliable and therefore participants should use a double-barrier method (e.g., male condom+either diaphragm or cervical cap with or without spermicide).
* An IUS does not rely on systemic plasma concentrations and is therefore not expected to be impacted by a potential drug-drug interaction (DDI)
Note 1: Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
Note 2: A male and female condom should not be used together due to risk of breakage or damage caused by latex friction
7. A post-menopausal female who is receiving hormone replacement therapy and is willing to discontinue hormone therapy 30 days before study drug dosing and agrees to remain off hormone replacement therapy for the duration of the study may be eligible for study participation.
* Male participants must either:
* be surgically sterile (had a vasectomy), or otherwise incapable of fathering a child, OR
* not be heterosexually active (e.g., abstinent or homosexual) from enrollment (Day 1) in the study until at least 6 months after study drug administration, OR
* if heterosexually active:
* have a partner who is postmenopausal (2 years amenorrhea), surgically sterile (e.g., has had a total hysterectomy, bilateral oophorectomy, or bilateral tubal ligation/bilateral tubal clips without reversal operation), or otherwise incapable of becoming pregnant OR
* be practicing an acceptable method of birth control from enrollment in the study (Day 1) and agree to continue to use the same method of contraception throughout the study and for at least 6 months after study drug administration (or longer, if dictated by local regulations). An acceptable method of birth control for male participants is a double-barrier method (e.g., male condom+either diaphragm or cervical cap with or without spermicide).
Note: Male participants with a female partner who uses hormonal contraceptives (oral, injectable, implants) or a hormonal (IUS) or non-hormonal IUD and male participants who are vasectomized or otherwise incapable of fathering a child are not required to use additional contraceptive methods.
Note 1: Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
Note 2: A male and female condom should not be used together due to risk of breakage or damage caused by latex friction.
8. Participants must agree to refrain from sperm/egg donation from start of dosing through 6 months after the completion of study drug administration
9. Genotype (GT) 1a or 1b or GT2 or 3 chronic hepatitis C (CHC), depending on cohort, with positive Hepatitis C virus (HCV) antibody and a positive HCV ribonucleic acid (RNA) at screening including documentation of CHC infection for at least 6 months. Genotype testing must occur at a screening visit. NOTE: GT1 patients are eligible for inclusion even if they cannot be successfully subtyped unless a specific subtype is required for a cohort
10. Screening HCV RNA viral load greater than or equal to (\>=) 50,000 International Units per milliliter (IU/mL), except for participants with compensated cirrhosis (Child Pugh Class A) who may have HCV RNA viral load \>=10\^4 IU/mL
11. No prior treatment for CHC (defined as no prior exposure to any approved or investigational drug including direct-acting antivirals, and interferon-based treatments)
12. Fibroscan, collected within 6 months of baseline visit, with liver stiffness score less than or equal to (\<=) 12.5 kilo Pascal (kPa) to be eligible (except for participants with cirrhosis, see below).
* participants with compensated cirrhosis must meet the Child-Pugh Class A definition (see Appendix G) and at least one of the following criteria: i. Liver biopsy result indicating the presence of cirrhosis (e.g., Metavir F4; Ishak \>5) or ii. Fibroscan evaluation with a liver stiffness score \>12.5 kPa
13. Participant is otherwise in good health as deemed by the investigator, based on the findings of a medical evaluation including medical history, physical examination, laboratory tests and electrocardiogram (ECG)
14. Willing to avoid prolonged sun exposure and use of tanning devices while taking Simeprevir (SMV) and through 4 weeks of follow up. Participant should also be advised to use a broad-spectrum sunscreen and lip balm of at least sun protection factor \>30 to help protect against potential sunburn
Exclusion Criteria
2. Other than CHC with or without compensated cirrhosis, clinically significant cardiovascular, respiratory, renal, gastrointestinal, hematologic, neurologic, thyroid or any other medical illness or psychiatric disorder, as determined by the Investigator and/or Sponsor's Medical Monitor
3. History or other clinical evidence of significant or unstable cardiac disease (e.g., angina, congestive heart failure, myocardial infarction, diastolic dysfunction, significant arrhythmia, coronary heart disease, and/or clinically significant ECG abnormalities), moderate to severe valvular disease or uncontrolled hypertension at screening
4. Screening echocardiogram ejection fraction \<55 percentage (%) or any other echocardiographic finding suggestive of clinically relevant cardiomyopathy
5. Creatinine clearance of \<60 mL/min (Cockcroft-Gault)
6. Positive test for Hepatitis A virus immunoglobulin (HAV) Immunoglobulin M (IgM), Hepatitis B surface antigen (HBsAg), or Human Immunodeficiency Virus (HIV) Ab
7. Abnormal screening laboratory results that are considered clinically significant by the investigator
8. History of clinical hepatic decompensation, e.g., variceal bleeding, spontaneous bacterial peritonitis, ascites, hepatic encephalopathy or active jaundice (within last year)
9. Any condition that, in the opinion of the investigator, would compromise the study's objectives or the well-being of the participant or prevent the participant from meeting the study requirements
10. Participation in an investigational drug trial or having received an investigational vaccine within 30 days or 5 half lives (whichever is longer) prior to study medication
11. Clinically significant abnormal screening ECG findings (e.g., PR \>200 msec, QRS interval \>120 millisecond (msec) or corrected QT interval (QTc) \>450 msec for male participants and \>470 msec for female participants), based on an average of triplicate ECGs. Any evidence of heart block or bundle branch block is also exclusionary
12. History or family history of abnormal ECG intervals, for example prolonged QT syndrome (torsade de pointes) or sudden cardiac death
13. The participant has a positive prestudy drug screen, including methadone unless the drug is prescribed by the participant's physician. The list of drugs that should be screened for includes amphetamines, barbiturates, cocaine, opiates, phencyclidine (PCP), and benzodiazepines
14. Laboratory abnormalities including:
* Hematocrit \<0.34
* White blood cell counts \<3,500/millimeter (mm)\^3 (\<1,000/mm\^3 for participants with compensated cirrhosis)
* Absolute neutrophil count \<1,000/mm\^3 (\<750/mm\^3 for participants with compensated cirrhosis)
* Platelets \<=120,000/mm\^3 (platelets ≤90,000/mm\^3 for participants with compensated cirrhosis)
* Glycosylated hemoglobin (HbA1C) \>55 mmol/mol
* Prothrombin time \>=1.5 \* upper limit of normal (ULN)
* Albumin \<=32 gram per liter (g/L), bilirubin \>=1.5 milligram per deciliter (mg/dL) at screening (participants with documented Gilbert's disease allowed)
* Serum ALT concentration \>=5\* ULN
* CK \>1.5\* ULN A single repeat laboratory evaluation under appropriate conditions (e.g., fasted, no antecedent exercise) is allowed for eligibility determination
15. Any condition possibly affecting drug absorption (e.g., gastrectomy or other significant gastrointestinal tract surgery, such as gastroenterostomy, small bowel resection, or active enterostomy)
16. Clinically significant blood loss or elective blood donation of significant volume (i.e., \>500 mL) within 60 days of first dose of study drug; \>1 unit of plasma within 7 days of first dose of study drug
17. Evidence of clinically relevant active infection that would interfere with study conduct or its interpretation
18. History of regular alcohol intake \>10 standard drinks per week of alcohol for females and \>15 standard drinks per week for males (one unit is defined as 10 g alcohol) within 3 months of the screening visit
19. The use of prohibited medications, including prescription, over the counter (OTC) medications, herbal medications, inducers or inhibitors of Cytochrome P450 (CYP450) enzymes or drug transporters (including P-gp) within 14 days prior to the first dose of study medication is excluded, unless previously approved by the Sponsor's Medical Monitor. NOTE: Chronic medication use is permitted so long as they are medically necessary, deemed acceptable by the Principal Investigator and Medical Monitor, and not Prohibited Medications (see Section 5.12)
20. Hypersensitivity to the active substances (including sulfa allergy) or to any of the excipients of AL-335, Odalasvir (ODV) or SMV
21. Evidence on recent (within 6 months) liver ultrasound of hepatic mass or lesion concerning for malignancy (participants with cirrhosis only)
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alios Biopharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alios Biopharma Inc. Clinical Trial
Role: STUDY_DIRECTOR
Alios Biopharma Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CAP Research Ltd
Phoenix, , Mauritius
Republican Clinical Hospital
Chisinau, , Moldova
Auckland Clinical Studies
Auckland, , New Zealand
Christchurch Clinical Studies Trust
Christchurch, , New Zealand
Waikato Hospital
Hamilton, , New Zealand
P3 Research Ltd - Hawkes Bay
Havelock North, , New Zealand
P3 Research Ltd - Wellington
Wellington, , New Zealand
Wellington Hospital
Wellington, , New Zealand
King's College Hospital
Brixton, , United Kingdom
NHS Greater Glasgow and Clyde Glasgow Royal Infirmary
Glasgow, , United Kingdom
Pennine Acute Hospitals Trust
Oldham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AL-335-604
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.